Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Sedighi, Abdolazim; Hamed, Ehsan Akbari; Mohammadian, Kamal; Behnood, Sepideh; Kalaghchi, Bita

doi:10.7314/apjcp.2013.14.12.7381

Cited by 8 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On correlating age with ER and PR status, hormone receptor positivity was found to be more common in elderly patients as has been found in literature (Sofi et al, 2012). Men comprise of only around 1% of all diagnosed breast cancers (Sedighi et al, 2013). As found in literature as well as the current study, upper outer quadrant is the most common siteof primary breast tumor (Sofi et al, 2012).…”

Section: Discussionsupporting

confidence: 77%

Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution

Ghosh

Sarkar²,

Simhareddy³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Breast cancer is the most common malignancy in women worldwide and the second most common cancer in females in India. Receptor status may be important for survival. Objective: To analyse and correlate the clinical and morphological parameters with receptor status in breast carcinoma patients in a tertiary care institution in Southern India. Materials and Methods: This retrospective study involved 320 patients of breast cancer diagnosed in an oncology hospital over a period of 3½ years. Data was analysed using SPSS Version 21. Results: Some 60.6% patients with breast carcinomas belonged to the age group of 40 to 60 years. The most common histological type was infiltrating ductal carcinoma, not otherwise specified, accounting for 84.4% of patients. On immunohistochemistry, estrogen receptor (ER) and progesterone receptor (PR) were expressed in 56.3% and 53.1% of cases, respectively. Conclusions: Breast cancers in India, a developing country, occur in younger women and tend to be more aggressive with lower rates of ER and PR expression and higher histological tumor grades. Both ER and PR status of the tumors had significant associations with the patient age, pathological TNM stage and histological tumor grade.

show abstract

Section: Discussionsupporting

confidence: 77%

Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution

Ghosh

Sarkar²,

Simhareddy³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Given the rarity of the disease, most of the information regarding its characteristics, management and outcome is based on either retrospective studies of a small number of patients or extrapolation of the results of female breast cancer (FBC). (Giordano et al, 2004;Nahleh et al, 2007;Sedighi et al, 2013) Recently published data in the United(surgery, chemotherapy and radiotherapy), and outcome (follow up, recurrence and five year survival).…”

Section: Introductionmentioning

confidence: 99%

Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan

Jamy

Rafiq²,

Laghari³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

States has shown a significant increase in the incidence of MBC whereas a steady low rate has been observed in European studies. (Kaushik et al., 2014) There is still a paucity of randomized controlled trials and treatment for MBC is based on treatment for FBC.The general variation of MBC across the globe is similar to FBC with higher rates in North America and Europe and lower rates in Asia. (Chikaraddi et al., 2012;Kaushik et al., 2014) Materials and MethodsThis retrospective review was carried out at The Aga Khan University Hospital (AKUH) in Karachi, Pakistan. Approval was obtained from the ethics committee at AKUH. Files with ICD code 175 (Malignant neoplasm of male breast) were retrieved from patient medical records. A total of 19 patients with MBC were seen at our institute between January 1986 and December 2009. One patient with missing records was excluded from the study. Data from 18 files were reviewed and analyzed.The variables studied were age at diagnosis, comorbid conditions, presenting signs and symptoms (breast lump, erythema, nipple discharge and axillary lymphadenopathy), family history of breast cancer, smoking history, diagnostic modality, histopathology including hormonal work up, TNM staging, treatment

show abstract

“…Breast cancer remains a significant problem for global health as it is one of the most common cause of tumorrelated death world-wide (Fouz et al, 2013;Engin et al, 2013;Sedighi et al, 2013;Zhu et al, 2013;Wu et al , 2014;Cabuk et al, 2014;Chin et al, 2014;Fouladi et al, 2014;Majeed et al, 2014;Gogia et al, 2014;Liu et al, 2014;Louisa et al, 2014;Moazzezy et al, 2014;Niu et al, 2014;Rizalar et al, 2014;Sipetic-Grujicic et al, 2014;Prajoko et al, 2014;Inanc et al, 2014;Varol et al, 2014;Yadav et al, 2014). Pemetrexed is a novel multitargeted antifolate that inhibits several enzymes in the de novo pathways of pyrimidine and purine biosynthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide ormyltransferase.…”

Section: Discussionmentioning

confidence: 99%

A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

Wan

Chen²,

Dong³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Cited by 8 publications

References 7 publications

Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution

Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution

Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan

A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

Contact Info

Product

Resources

About